heart failure
Cardiovascular · 2005–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eplerenone Chronic heart failure with left ventricular ejection fraction ≤40% (NYHA Class II-IV), and post-acute myocardial infarction heart failure (within 3-14 days of… | Dec 2025 | Recommended with restriction | input received |
| empagliflozin Chronic heart failure in patients symptomatic with NYHA classes II, III or IV with documented left ventricular ejection fraction (LVEF) of less than or equal… | Mar 2024 | Recommended with restriction | none received |
| sacubitril with valsartan Amendment to PBS listing to allow nurse practitioners to initiate sacubitril with valsartan for the treatment of chronic heart failure with reduced ejection… | Nov 2024 | Recommended | input received |
| dapagliflozin Treatment of chronic heart failure patients with left ventricular ejection fraction (LVEF) greater than 40% who are receiving standard of care therapy. | Jul 2023 | Recommended with restriction | input received Diabetes Australia |
| vericiguat Treatment of symptomatic (NYHA class II, III or IV) chronic heart failure in patients with reduced ejection fraction (LVEF <45%) who are stabilised after a… | Jul 2022 | Recommended with restriction | none received |
| vericiguat Treatment of symptomatic chronic heart failure (NYHA class II, III, IV) with reduced ejection fraction (LVEF <45%) in patients stabilised after recent… | Mar 2022 | Not recommended | input received |
| empagliflozin Treatment of chronic heart failure (NYHA classes II, III, or IV) in patients with left ventricular ejection fraction greater than 40%. | Dec 2022 | Not recommended | input received Diabetes Australia |
| dapagliflozin Treatment of patients with symptomatic heart failure with reduced ejection fraction (HFrEF) who are receiving concomitant optimal standard chronic heart… | Sep 2021 | Deferred | input received Diabetes Australia · National Aboriginal Community Controlled Health Organisation |
| empagliflozin Treatment of patients with chronic heart failure with reduced ejection fraction (HFrEF), New York Heart Association classification II-IV, left ventricular… | Nov 2021 | Recommended with restriction | input received |
| sacubitril/valsartan Chronic heart failure (NYHA class II-IV) with reduced left ventricular ejection fraction (≤40%) in patients with previous or current exposure to ACE inhibitors… | Jul 2016 | Noted | input received |
| ivabradine Chronic heart failure in symptomatic patients (NYHA classes II or III) with reduced left ventricular ejection fraction (≤35%) and elevated resting heart rate… | Mar 2015 | Recommended with restriction | no section in document |
| ivabradine Treatment of symptomatic systolic heart failure in patients in sinus rhythm with heart rate ≥75 bpm, stabilised on optimal heart failure therapy including ACE… | Jul 2012 | Not recommended | no section in document |
| ivabradine Symptomatic systolic heart failure in patients in sinus rhythm with heart rate of at least 75 bpm (later amended to ≥77 bpm per TGA approval), stabilised on… | Nov 2012 | Deferred | no section in document |
| ivabradine Symptomatic systolic heart failure in patients in sinus rhythm with heart rate at or above 70 bpm stabilised on conventional therapy including a beta blocker… | Nov 2011 | Not recommended | unclear |
| nebivolol hydrochloride Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II receptor antagonist (if… | Nov 2009 | Recommended with restriction | no section in document |
| nebivolol hydrochloride Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II receptor antagonist (if… | Nov 2009 | Recommended with restriction | no section in document |
| eplerenone To reduce the risk of cardiovascular death in combination with standard medical therapy in patients who have evidence of heart failure and left ventricular… | Jul 2005 | Recommended with restriction | no section in document |
Who spoke
Diabetes Australia · National Aboriginal Community Controlled Health Organisation
What the PBS pays
$525M in government benefit over 2024–25, across 9,232,609 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| sacubitril with valsartan | $191.3M |
| empagliflozin | $186.5M |
| dapagliflozin | $114.2M |
| nebivolol hydrochloride | $19.3M |
| eplerenone | $4.9M |
| Ivabradine | $3.5M |
| ivabradine | $3.5M |
| vericiguat | $1.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 4 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| empagliflozinEmpagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | recommended | 2023-11 |
| dapagliflozinDapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | recommended | 2023-06 |
| sacubitril valsartanSacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | recommended restricted | 2016-04 |
| ivabradineIvabradine for treating chronic heart failure | TA267 | recommended | 2012-11 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| candesartan cilexetilADESAN candesartan cilexetil 16 mg tablet blister pack | 1998 | 124 |
| carvedilolAPO-CARVEDILOL carvedilol 12.5 mg tablet blister pack | 1998 | 62 |
| bisoprololAPO-BISOPROLOL bisoprolol fumarate 1.25mg tablet blister pack | 2002 | 61 |
| perindopril erbumineAPO-PERINDOPRIL perindopril erbumine 2mg tablets blister pack | 1992 | 38 |
| sodium nitroprussideDBL SODIUM NITROPRUSSIDE CONCENTRATED INJECTION sodium nitroprusside 2 | 2012 | 10 |
| digoxinLANOXIN PAEDIATRIC Elixir | 1991 | 9 |
| quinaprilGENRX QUINAPRIL TABLETS quinapril 20mg (as hydrochloride) tablets blis | 2006 | 8 |
| dobutamineDBL DOBUTAMINE 250mg/20mL (as hydrochloride) injection | 1991 | 7 |
| fosinoprilAPO-FOSINOPRIL fosinopril sodium 10mg tablet bottle | 2004 | 6 |
| prazosinAPO-PRAZOSIN prazosin (as hydrochloride) 1mg tablet blister pack | 1991 | 6 |
| milrinoneMILRINONE-BAXTERmilrinone (as lactate) 10 mg/10 mL concentrated inject | 2013 | 3 |
| chlortalidoneHYGROTON 25 chlortalidone 25mg tablet bottle | 1991 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.